Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Proteros and Eisai Achieve Target in Lead Discovery Project

Published: Tuesday, May 07, 2013
Last Updated: Tuesday, May 07, 2013
Bookmark and Share
Companies delivering kinetically optimized lead compounds.

Proteros biostructures GmbH announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months.

The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity. Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.

Dr. Lars Neumann, Vice President Discovery Projects and Project Manager stated: “We are very satisfied with the course of the project and are pleased to deliver the lead compound series to our partner Eisai Co., Ltd. We look forward to contributing further to the success of the Eisai research pipeline using our unique technology platform.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros Elects New Supervisory Board Member
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.
Thursday, February 20, 2014
Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
Companies partner to identify small molecule inhibitors.
Monday, April 16, 2012
Proteros and SUPERGEN Enter Into an Integrated Lead Discovery Agreement
Under the agreement, Proteros will collaborate on the discovery of small molecule lead compounds against a specific target of interest.
Friday, February 04, 2011
Proteros Enters into a Research Agreement for Structure Based Lead Generation
Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD.
Tuesday, September 28, 2010
Proteros Announces Expansion of Commercial Organization in USA and Japan
Company has confirmed its annual financial statement for 2009, which showed a growth rate, in revenues, in excess of 30% while maintaining profitability.
Friday, August 13, 2010
Proteros Biostructures Announces Collaboration with UCB
Proteros to leverage its expertise in gene-to-structure projects and technologies to solve the three dimensional structure of an undisclosed target.
Monday, March 09, 2009
Proteros Biostructures Raises 5.2 Million Euros for Business Expansion
The capital provided by BayBG will be utilized for increasing service capacity and expanding the fragment screening and protein production areas.
Thursday, August 23, 2007
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!